Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alumis
Biotech
Alumis pulls back from would-be rival to Amgen’s Tepezza
Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather than enter phase 3.
Nick Paul Taylor
May 15, 2026 3:44am
Alumis beams as pivotal data on Sotyktu rival drive stock surge
Jan 6, 2026 9:05am
Sarepta shakes up C-suite amid org overhaul—Chutes & Ladders
Jul 18, 2025 8:30am
Activist investor fails to derail Alumis' Acelyrin merger
May 14, 2025 7:45am
Investor pressures Acelyrin to exit Alumis merger and liquidate
Apr 30, 2025 10:30am
Kaken pens $180M pact for Alumis' lead TYK2 inhibitor in Japan
Mar 25, 2025 6:55am
